Skip to content

Application of a novel traction device in endoscopic submucosal dissection for early gastric cancer and precancerous lesion - a single center retrospective clinical trail

Application of a novel traction device in endoscopic submucosal dissection for early gastric cancer and precancerous lesion - a single center retrospective clinical trail

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104297
Enrollment
Unknown
Registered
2025-06-13
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer and precancerous lesion

Interventions

Traditional ESD resection for early gastric cancer group:NA
Traction assisted ESD resection for early gastric cancer group:NA

Sponsors

The Second Hospital & Clinical Medical School,Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age 18 and above; (2) Early gastric cancer and precancerous lesion is diagnosed through magnifying endoscopy or staining endoscopy, and the tumor is located at the gastric fundus, gastric body, or gastric angle with a diameter of >= 20mm; (3) The tumor meets the absolute and expanded indications of the Japanese Gastric Cancer Treatment Protocol (Second Edition): a. Differentiated adenocarcinoma within the mucosal layer, without ulcers; b. Differentiated adenocarcinoma within the mucosal layer of combined ulcers, <= 30mm; (4) Preoperative pathological biopsy diagnosis is consistent with gastric cancer group subtypes 3, 4, and 5; (5) Patient activity status ECOG score 0-2.

Exclusion criteria

Exclusion criteria: (1) Preoperative diagnosis of early gastric cancer patients with invasion depth reaching the submucosal deep layer (>= SM2); (2) Enhanced CT scan of the abdomen revealed lymph node metastasis; (3) Cases of local recurrence after endoscopic resection; (4) Patients with active malignant tumors outside the stomach; (5) Severe anemia, coagulation dysfunction, heart, lung, liver, and kidney dysfunction, severe acute infection, and pregnant patients; (6) Unable to tolerate intravenous anesthesia cases; (7) Anticoagulants and anticoagulants (excluding low-dose aspirin) cannot be discontinued; (8) Patients who are currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Resection speed;

Secondary

MeasureTime frame
Endoscopic resection time;muscular injury;Total local injection volume;Intraoperative perforation;

Countries

China

Contacts

Public ContactPengfei Wang

The Second Hospital & Clinical Medical School, Lanzhou University

wpfw@foxmail.com+86 181 5367 3602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026